Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Wake Up Narcolepsy launched a WUN Narcolepsy Awareness Apparel Fundraiser in conjunction with their 2019...
On Tuesday, November 19, 2019, Wake Up Narcolepsy joined Project Sleep, the Sleep Research Society...
Harmony Biosciences has published two informative clinical studies evaluating the long-term safety and efficacy, as...
Calling all adolescents with narcolepsy, parents, and medical providers: Wake Up Narcolepsy, in collaboration with researchers,...
For the past 8 years Wake Up Narcolepsy has taken portions of funds raised during...
Great News! Wakix is a newly approved treatment for Excessive Daytime Sleepiness (EDS) and as a...
JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number...
Four organizations will receive grants totaling $65,000 to support programs that help address unmet needs...
We are excited to announce that Dr. Jason Ong, part of WUN's Medical Advisory Board,...